Editas Medicine (EDIT) Other financing activities (2016 - 2025)

Editas Medicine (EDIT) has 10 years of Other financing activities data on file, last reported at $228000.0 in Q3 2025.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $228000.0 in Q3 2025; TTM through Sep 2025 was $626000.0, a 43.09% decrease from a year earlier, with the FY2024 full-year figure at $590000.0, down 35.8% from the prior year.
• Other financing activities for Q3 2025 stood at $228000.0, down from $398000.0 in the prior quarter.
• Over the last five years, Other financing activities for EDIT reached as high as $31.0 million in Q4 2021 and fell as low as -$28.0 million in Q3 2021.
• Historically, Other financing activities has averaged $2.4 million across 5 years, with a median of $223000.0 in 2022.
• On a YoY basis, Other financing activities climbed as much as 12871.43% in 2023 and fell as far as 514.49% in 2023.
• Year by year, Other financing activities stood at $31.0 million in 2021, then tumbled by 99.98% to $7000.0 in 2022, then soared by 12871.43% to $908000.0 in 2023, then slumped by 56.17% to $398000.0 in 2024, then sank by 42.71% to $228000.0 in 2025.
• Per Business Quant data, the three most recent Other financing activities figures were $228000.0 in Q3 2025, $398000.0 in Q4 2024, and $192000.0 in Q1 2024.